Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism

Lankeit Mareike, Jiménez David, Kostrubiec Maciej, Dellas Claudia, Kuhnert Katherina, Hasenfuß Gerd, Pruszczyk Piotr, Konstantinides Stavros

Source: Eur Respir J 2014; 43: 1669-1677
Journal Issue: June
Disease area: Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slidesCME test or case report

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Lankeit Mareike, Jiménez David, Kostrubiec Maciej, Dellas Claudia, Kuhnert Katherina, Hasenfuß Gerd, Pruszczyk Piotr, Konstantinides Stavros. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43: 1669-1677

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The prognostic value of repeated measurements of N-terminal pro-B-type natriuretic peptide in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010


Correlation of levels of N-terminal pro-B-type natriuretic peptide with localization of thrombus in acute pulmonary embolism
Source: Annual Congress 2011 - Clinical features of pulmonary thromboembolism
Year: 2011

Diagnostic value of N-terminal pro-brain natriuretic peptide levels in pleural effusions of cardiac origin
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010


The use of plasma n-terminal pro B-type natriuretic peptide (proBNP) concentrations in differential diagnosis of comorbidity pulmonary patients
Source: Annual Congress 2011 - Acute respiratory failure
Year: 2011


N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism
Source: Eur Respir J 2003 Oct 01;22(4):649-653
Year: 2003



Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH
Source: ERJ Open Res, 6 (4) 00356-2020; 10.1183/23120541.00356-2020
Year: 2020



Prognostic significance of amino-terminal pro-brain natriuretic peptide testing among waitlisted lung transplant candidates
Source: Virtual Congress 2021 – Challenging problems in lung transplantation
Year: 2021

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension
Source: Eur Respir J 2010; 35: 95-104
Year: 2010



The role of pro-brain natriuretic peptide and C-reactive protein as prognostic markers in stable COPD
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007


Diagnostic value of N-terminal pro-brain natriuretic peptide in patients with COPD with chronic hypoxemic respiratory failure.
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020


Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP
Source: Eur Respir J 2011; 37: 595-603
Year: 2011



The diagnostic value of N-terminal pro-C-type natriuretic peptide in COPD patients with pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015


N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pulmonary hypertension and renal insufficiency
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013


Can brain natriuretic peptide (BNP) be a predictor for pulmonary arterial hypertension?
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007



Plasma n-terminal pro-brain natriuretic peptide (NT pro-BNP) level in respiratory diseases
Source: Eur Respir J 2003; 22: Suppl. 45, 583s
Year: 2003

The role of N-terminal pro B-type natriuretic peptide in predicting mortality of community acquired pneumonia
Source: International Congress 2019 – Pneumonia in 2019: antimicrobial resistance, cardiovascular complications and diagnosis
Year: 2019




Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 481s
Year: 2007

Prognostic value of serum N-terminal brain natriuretic peptide type B for pulmonary hypertension among patients with usual interstitial pneumonia and sarcoidosis
Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases
Year: 2007


A point-of-care brain natriuretic peptide assay in the risk stratification and management of patients with pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 48s
Year: 2006

Brain natriuretic peptide (BNP) levels during acute exacerbations of COPD – a novel biomarker
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008